Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | TACR1 | P25103 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29587852 | 1.00 | ALDH1A1 (0.58) | ALDH1A1TACR1GAAATMMAPT | |
| SCHEMBL1913626 | 0.88 | ALDH1A1 (0.55) | ALDH1A1ATMMAPTL3MBTL1TDP1 | |
| SCHEMBL18171808 | 0.88 | MAPT (0.60) | ALDH1A1ATMMAPTL3MBTL1TDP1 | |
| SCHEMBL25414162 | 0.87 | CTSB (0.49) | ALDH1A1TACR1CTSB | |
| SCHEMBL25414161 | 0.87 | CTSB (0.49) | ALDH1A1TACR1CTSB | |
| SCHEMBL15080869 | 0.87 | CTSK (0.61) | ATMCTSLCTSB | |
| SCHEMBL30946598 | 0.87 | CTSK (0.61) | ATMCTSLCTSB | |
| SCHEMBL23056471 | 0.85 | MAPT (0.54) | ALDH1A1ATMMAPTL3MBTL1TDP1 | |
| SCHEMBL8823266 | 0.85 | ALDH1A1 (0.59) | ALDH1A1TACR1ATML3MBTL1TDP1 | |
| SCHEMBL22692566 | 0.84 | ALDH1A1 (0.58) | ALDH1A1ATMMAPTL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731938-B2 | Ultra short acting anti-arrhythmic agents | ACADEMIC PHARMACEUTICALS INC (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731938-B2 | Ultra short acting anti-arrhythmic agents | CACNA1G, SCN5A, CACNA1F | ALDH1A1 1515/4885TACR1 3353/4885GAA 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.